Newsroom
Press Releases
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved...
Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
Data reinforce brilaroxazine's differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors...
Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform
CUPERTINO, Calif., May 19, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing...
Articles & Videos
KOL Webinar Video Replay: Brilaroxazine: a serotonin/dopamine modulator in late-stage development for Schizophrenia
May 2, 2023 | KOL webinar video replay featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals, and Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research).
KOL Webinar Slide Presentation: Brilaroxazine: a serotonin/dopamine modulator in late-stage development for Schizophrenia
May 2, 2023 | KOL webinar slide presentation featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals, and Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research).
Reviva: Nasdaq Amplify Issuer Spotlight
April 27, 2023 | Reviva was the Nasdaq Amplify Issuer Spotlight in the April 2023 edition of the Nasdaq Amplify Newsletter. Laxminarayan Bhat, CEO Reviva Pharmaceuticals, discusses Reviva’s pipeline and commitment to developing better, safer, and more effective treatment options.
Reviva: Phase 3 Trial in Schizophrenia Now Underway
April 22, 2023 | Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals discussing the Company’s Phase 3 trial for schizophrenia and much more.
Reviva Webcast at the 35th Annual Roth Conference
March 13, 2023 | Laxminarayan Bhat, CEO of Reviva Pharmaceuticals, presented at the 35th Annual Roth Conference
Reviva: Next Generation Blockbuster
March 10, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses Brilaroxazine’s potential to safely improve quality of life for schizophrenia patients.
Reviva's Brilaroxazine Addresses Antipsychotics' Biggest Hurdles
March 10, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses Brilaroxazine’s favorable efficacy profile along with how it addresses the Positive and Negative Syndrome Scale (PANSS).
Reviva's Clinical & Regulatory Timelines
March 10, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses the company’s timelines over the next several quarters with respect to topline data readouts, FDA interaction and when we should see the second Phase III trial for Brilaroxazine.
Reviva: More Than Schizophrenia
March 10, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO shares the future of the company in other indications including Bipolar Disorder, Major Depressive Disorder, ADHD, Pulmonary Arterial Hypertension and Idiopathic Pulmonary Fibrosis.
Fireside Chat: Reviva's RP1208 & Thoughts on Peers
March 10, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses Brilaroxazine’s favorable efficacy profile along with how it addresses the Positive and Negative Syndrome Scale (PANSS).
Reviva: The Potential Future Standard of Care for Schizophrenia
October 15, 2022 | Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals
New Schizophrenia Drug Shows Promise of Greater Success with Fewer Side Effects
May 5, 2022 | RealClear Health article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals
Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders
May 3, 2022 | KOL Webinar featuring Leslie Citrome, MD (New York Medical College), Larry Ereshefsky, PharmD (Apex Innovative Sciences), and Laxminarayan Bhat, CEO (Reviva Pharmaceuticals)
Unboxing Biotech Video Series
March 9, 2022 | A 4-part video series with John Vandermosten of Zacks Research featuring Reviva Pharmaceuticals CEO Laxminarayan Bhat
Engineered neuroreceptor-specificity set to deliver next-generation schizophrenia therapeutics
June 2021 | Nature Research article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals
This page contains links to other third party sites. Clicking on a third party link will cause you to leave our website. The third party sites are not controlled by Reviva and we are not responsible for the content. Please see our Privacy Policy for more information regarding third party links and sites.